Navigation Links
ResMed Announces Conference Call And Webcast To Discuss Fourth Quarter And Fiscal Year-End 2012 Results

SAN DIEGO, June 28, 2012 /PRNewswire/ -- RESMED INC. (NYSE: RMD) announced today that on Thursday, August 2, 2012, it will release its results for the fourth quarter and fiscal year ended June 30, 2012. A press release with ResMed's results will be issued after 1:00 p.m. Pacific Time and the company will host a conference call and webcast to review its results, market trends, and future outlook.


The conference call is scheduled to begin at 1:30 p.m. Pacific Time and will be webcast on ResMed's website at Please go to this section of the website 5-10 minutes before the call and click on the icon for the "Q4 2012 results webcast." The online archive of the broadcast will be available approximately 30 minutes after the live call and will continue to be available for two weeks.

International conference call times will be:9:30 p.m.

London6:30 a.m.

Sydney, Australia (August 3, 2012)TO PARTICIPATE in the conference call, please call one of the numbers below at least 10 minutes before the call begins and identify yourself to the operator:


617-597-5377 Outside US:

+1 617-597-5377Conference Name:

Q4 2012 ResMed Inc. Results Conference Call  Participant Passcode:

68952697The replay of the conference call will be available approximately 30 minutes after the call and will be accessible for two weeks at:


617-801-6888Outside US:

+1 617-801-6888Passcode:

18538587ResMed is a global leader in the development, manufacturing, and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing.

Further information can be obtained by contacting Constance Bienfait at ResMed Inc. at +1 (858) 836-5971, or by visiting the company's website at

SOURCE ResMed Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ResMed Inc. Announces Plan To Initiate Dividend And Update On Chief Executive Officer Succession
2. ResMed Launches Narval™ CC Mandibular Repositioning Device in the US
3. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
4. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
6. Misonix Announces New Distribution Agreement For Panama
7. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
9. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
10. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
11. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015  Six months of adjunctive metformin therapy ... 1 diabetes, according to new research from T1D Exchange ... may have a beneficial effect on measures of obesity, including ... of the Journal of the American Medical Association , ... effect of metformin on overweight and obese adolescents with type ...
(Date:12/1/2015)... 1, 2015 During the recent 2015 ... San Francisco, CA , Medinol Ltd. continued ... marketplace. During a satellite symposium, "The BioNIR eDES: ... Minimize Restenosis", a renowned physician panel discussed the ... CoCr Coronary Stent System and the Medinol eDES ...
(Date:12/1/2015)... Russia has always been a country of choice for ... Europe in 2015 were tested in phase II-III ... has always been a country of choice for global multi-center phase ... in 2015 were tested in phase II-III clinical trials ... always been a country of choice for global multi-center phase III clinical ...
Breaking Medicine Technology:
(Date:12/1/2015)... MA (PRWEB) , ... December 01, 2015 , ... It’s ... has a tattoo — a number even greater among Millennials (a whopping one in ... are more and more people who are dissatisfied with their ink. In fact, ...
(Date:12/1/2015)... ... 01, 2015 , ... The importance of volumetric breast density ... of numerous abstracts accepted for presentation here, at the 101st Annual Radiology Society ... the use of Volpara Solutions’ quantitative breast imaging software tools for providing breast ...
(Date:12/1/2015)... Diego, CA (PRWEB) , ... December 01, 2015 ... ... and scale , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro ... mobile imaging results enhancements at the Radiological Society of North America (RSNA) 2015 ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... it has been awarded a fixed price per sprint agile development contract to ... at $34 million over five years, provides software engineering, infrastructure, as well as ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s ... Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning healthcare ... once a deal is signed. This quick-read guidance suggests that failing to ...
Breaking Medicine News(10 mins):